About 5-hydroxytryptamine receptor 3E
5-hydroxytryptamine receptor 3E (HTR3E) is a protein
from Homo sapiens identified by UniProt accession
A5X5Y0, 456 residues long.
MolForge cross-references it against 0 known binders and
59 disease associations.
Target properties
| Protein name | 5-hydroxytryptamine receptor 3E |
| UniProt accession | A5X5Y0 |
| Gene | HTR3E |
| Organism | Homo sapiens |
| Length | 456 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (59)
Diseases linked to this target (Open Targets).
- schizophrenia · score 0.59
- post operative nausea and vomiting · score 0.57
- irritable bowel syndrome · score 0.54
- schizoaffective disorder · score 0.50
- type 2 diabetes mellitus · score 0.46
- Nausea and vomiting · score 0.46
- psychosis · score 0.46
- Chemotherapy-induced nausea and vomiting · score 0.44
- cancer · score 0.44
- Vomiting · score 0.43
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A5X5Y0-F1 | alphafold | PREDICTED | 80.83 | — |
Amino-acid sequence (456 residues)
MEGSWFHRKR FSFYLLLGFL LQGRGVTFTI NCSGFGQHGA DPTALNSVFN RKPFRPVTNI SVPTQVNISF AMSAILDVNE QLHLLSSFLW LEMVWDNPFI SWNPEECEGI TKMSMAAKNL WLPDIFIIEL MDVDKTPKGL TAYVSNEGRI RYKKPMKVDS ICNLDIFYFP FDQQNCTLTF SSFLYTVDSM LLDMEKEVWE ITDASRNILQ THGEWELLGL SKATAKLSRG GNLYDQIVFY VAIRRRPSLY VINLLVPSGF LVAIDALSFY LPVKSGNRVP FKITLLLGYN VFLLMMSDLL PTSGTPLIGV YFALCLSLMV GSLLETIFIT HLLHVATTQP PPLPRWLHSL LLHCNSPGRC CPTAPQKENK GPGLTPTHLP GVKEPEVSAG QMPGPAEAEL TGGSEWTRAQ REHEAQKQHS VELWLQFSHA MDAMLFRLYL LFMASSIITV ICLWNT
Explore 5-hydroxytryptamine receptor 3E with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets